

Supplemental Online Content

Corbett K, Sharma A, Pond GR, et al. Central nervous system–specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma. *JAMA Oncol*. Published online May 20, 2021.
doi:10.1001/jamaoncol.2021.1359

eAppendix. Methods

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix. Methods

The search term “cancer” was queried, along with the following advanced search criteria: study type: “All studies”; status: excluded “Not yet recruiting”; study results: “With Results”; and phase: “Phase 3”. No time limits were placed on the search criteria. This initial search yielded 1,860 results. Studies were then screened for randomized, multi-arm trials investigating a systemic therapy for a single disease site. Only studies that included patients with advanced (unresectable recurrent, locally advanced, refractory stage 3 or stage 4) breast, melanoma, or lung cancer were included because these malignancies are most likely to spread to the brain. Studies focused on leptomeningeal carcinomatosis in the absence of parenchymal BrM were excluded. Screening and parameter abstraction were performed by two independent reviewers (KC and AS), with discrepancies resolved by a third reviewer (KJJ). Proportions across groups were compared using Pearson’s chi-square tests at a level of significance of $p=0.05$.